BioSpace News Archive

NeuroHydrate, a healthcare startup, has quietly developed and market-tested HM-Formula, a new non-prescription migraine prevention supplement.

GUILFORD, CONN ., Feb. 19, 2020 /PRNewswire/ -- Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medica

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.

The Institute for Gene Therapies (IGT) launched today with a focus on advocating for a modernize the U.S. regulatory and reimbursement framework so that gene therapies can deliver their significant potential to patients.

Health Canada is advising Canadians that the following products may pose serious health risks.

Infrared Cameras Incorporated, manufactures P and S Series IR Cameras, which provide accurate skin surface temperature readings from the first 1/1000th inch of epidermal layer; another product, IR Flash Software version 1.0, visualizes this data and allows for report building functionalities.

Kowa Research Institute, Inc., announced the achievement of its goal to randomize 10,000 subjects into its international, multi-center Phase 3 cardiovascular outcomes trial titled “Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes” (PROMINENT).

RedDress, a privately held, Israel and U.S. based company, today announced the U.S. launch of ActiGraft, the first wound treatment that transforms – in real time – a patient’s blood into an autologous whole blood clot tissue

The Automated Insulin Delivery (AID) solutions developed by Diabeloop embed therapeutic artificial intelligence to automate and personalize Type 1 diabetes management.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its generic portfolio with the recent launch of three new products: Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP, and Clonidine Hydrochloride Extended-Release Tablets